The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL

Hemodialysis International

Volumn 12, Issue 1, 2008, Pages 100-107

  Doumouchtsis, Konstantinos K ^a,d   Kostakis, Alkis I ^a   Doumouchtsis, Stergios K ^a   Grapsa, Eirini I ^b   Passalidou, Ioanna A ^c   Tziamalis, Marios P ^c   Poulakou, Maria V ^a   Vlachos, Ioannis S ^a   Perrea, Despoina N ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c General Hospital of Kastoria   (Greece)

^d NONE   (Greece)

Author keywords

Bone mineral density; Hemodialysis; RANKL; Sexual hormones

Indexed keywords

CYTOKINE; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROLACTIN; SEX HORMONE; TESTOSTERONE; GONADOTROPIN DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; AGED; AGING; ARTICLE; BONE DENSITY; BONE MALFORMATION; BONE METABOLISM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FEMALE; FEMUR; HEMODIALYSIS; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RENAL OSTEODYSTROPHY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; CHRONIC KIDNEY FAILURE; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HORMONE DEFICIENCY; HORMONE DETERMINATION; LUTEINIZING HORMONE BLOOD LEVEL; MAINTENANCE THERAPY; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PROLACTIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; FEMALE; FEMUR; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HUMANS; KIDNEY FAILURE, CHRONIC; LUTEINIZING HORMONE; MALE; MIDDLE AGED; RANK LIGAND; REFERENCE VALUES; RENAL DIALYSIS; TESTOSTERONE;

EID: 39049101256     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00249.x     Document Type: Article

References (36)

1. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell. 2001; 104:719-730.
2. Oursler MJ, Pederson L, Fitzpatrick L, Riggs BL, Spelsberg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA. 1994; 91:5227-5231.
3. Pederson L, Kremer M, Judd J, et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci USA. 1999; 96:505-510.
4. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000; 106:1553-1560.
5. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001; 86:3555-3561.
6. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998; 83:2266-2274.
7. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: The MINOS study. J Clin Endocrinol Metab. 2001; 86:192-199.
8. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med. 2000; 133:951-963.
9. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab. 1999; 84:3626-3635.
10. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo study. J Bone Miner Res. 1997; 12:1833-1843.
11. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N, Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol (Oxf). 1998; 49:803-809.
12. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest. 1997; 100:1755-1759.
13. Huber DM, Bendixen AC, Pathrose P, et al. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology. 2001; 142:3800-3808.
14. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA. 2000; 97:7829-7834.
15. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem. 2001; 276:8836-8840.
16. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol. 1999; 13:819-828.
17. Hofbauer LC, Hicok KC, Chen D, Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol. 2002; 147:269-273.
18. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab. 2002; 87:1550-1554.
19. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone. 2003; 32:136-141.
20. Handelsman DJ. Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev. 1985; 6:151-182.
21. Gomez F, de la Cueva R, Wauters JP, Lemarchand-Beraud T. Endocrine abnormalities in patients undergoing long-term hemodialysis: The role of prolactin. Am J Med. 1980; 68:522-530.
22. Morley JE, Distiller LA, Epstein S, et al. Menstrual disturbances in chronic renal failure. Horm Metab Res. 1979; 11:68-72.
23. Van Kammen E, Thijssen JH, Schwarz F. Sex hormones in male patients with chronic renal failure. I. The production of testosterone and of androstenedione. Clin Endocrinol (Oxf). 1978; 8:7-14.
24. Handelsman DJ, Dong Q. Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am. 1993; 22:145-161.
25. de Vries CP, Gooren LJ, Oe PL. Haemodialysis and testicular function. Int J Androl. 1984; 7:97-103.
26. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999; 140:4367-4370.
27. Liao EY, Luo XH, Su X. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest. 2002; 25:785-790.
28. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab. 2001; 86:3162-3165.
29. Khosla S, Arrighi HM, Melton LJ III, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int. 2002; 13:394-399.
30. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab. 2002; 87:4470-4475.
31. Makhluf HA, Mueller SM, Mizuno S, Glowacki J. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. Biochem Biophys Res Commun. 2000; 268:669-672.
32. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001; 16:348-360.
33. Palmer BF. Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv Ren Replace Ther. 2003; 10:48-60.
34. Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998; 13:763-773.
35. Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res. 2005; 20:2224-2232.
36. Cunningham J. Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. J Am Soc Nephrol. 2007; 18:223-234.